Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Seite 2
Session Date and Time: Thursday, May 9, 2024, 12:00 p.m. ET
Session Title: Thursday Posters: Gene Disruption and Excision
Presentation Room: Exhibit Hall
Final Abstract Number: 1182
Title: Metagenomic Discovery and Screening of Novel Recombinase Proteins for Targeted Integration
Session Date and Time: Friday, May 10, 2024, 12:00 p.m. ET
Session Title: Friday Posters: Targeted Gene Insertion
Presentation Room: Exhibit Hall
Final Abstract Number: 1681
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of
treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines
for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human
medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Lesen Sie auch
Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’
‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the
initiation, timing, progress and results of the Company’s preclinical studies and its research and development programs, and the timing for the Company’s receipt and presentation of data from its
preclinical studies, including confirming in vivo proof-of-concept by the end of 2024. The Company may not actually achieve the plans, intentions, or expectations disclosed in
these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a result of various important factors, including uncertainties inherent in the initiation and completion of pre-clinical studies and
availability and timing of results from pre-clinical studies. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual
Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other
filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the
Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.